Small-cap pharma stock jumps 22% in two days after THESE bulk deals

Small-cap pharma stock Balaxi Pharmaceuticals has surged over 22% in the last two session, following bulk deal transactions. Balaxi Pharmaceuticals share price today opened at ₹57 apiece on the NSE, the stock touched an intraday high of ₹62.58 apiece, and an intraday low of ₹55.97 per share.

On March 3, Ebisu Global Opportunities Fund Limited purchased 45.21 lakh shares (8.19%) for ₹53 each. Unico Global Opportunities Fund Limited bought 45.77 lakh shares (8.3%) at the same price of ₹53 per share, as reported by the official data from the exchanges. Conversely, MGC Fund Limited sold 45.21 lakh shares, which also amounts to 8.19%, while Elala India Opportunities Fund offloaded 45.77 lakh shares (8.3%) at ₹53 per share.

Balaxi Pharma is a pharmaceutical company centered on branded intellectual property rights, targeting emerging markets and boasting an extensive and expanding range of medications across various therapeutic areas. The company’s market presence spans the Americas, Africa, and the Caribbean islands.

Financials

According to reports, Balaxi Pharma has reported a substantial increase in operational revenue, with a year-on-year growth of approximately 20.6%, climbing from Rs. 60.8 crores in Q3 FY24 to Rs. 73.3 crores in Q3 FY25.

Nonetheless, in the same timeframe, the company’s net profit fell from Rs. 12 crores to Rs. 5.4 crores, indicating a decline of about 55.2% year-on-year. EBITDA for Q3 FY25 saw a drop of 41.4% year-on-year, decreasing to Rs. 8 crores from Rs. 13.5 crores in Q3 FY24, while operating EBITDA margins also decreased by 1,144 basis points to 10.81%, from 22.25%, during that period.

Technical Views

According to Rajesh Bhosale, Equity Technical and Derivative Analyst at Angel One, this is a low volume counter, but have seen traction in the last few sessions, the positive momentum could continue towards 65 – 67 , whereas recent multiple lows around 50 would be key support.

Anshul Jain, Head of Research at Lakshmishree Investment and Securities explained that long consolidation presents a buying opportunity. Balaxi Pharma is forming a 238-week-long flat base, with strong outer boundaries at ₹57 (support) and ₹144 (resistance). Currently trading near the lower end of this range, the stock offers an attractive buy-the-dip opportunity for long-term investors. A bullish confirmation on the weekly chart could signal the start of an upside move, targeting ₹144. With sustained accumulation and a breakout above key levels, Balaxi Pharma could witness significant upside potential.

Disclaimer: The views and recommendations above are those of individual analysts, experts and broking companies, not of Mint. We advise investors to check with certified experts before making any investment decision.